Myqorzo MAPLE-HCM Label Update: Aficamten Beats Metoprolol as First-Line HCM Option
FDA adds MAPLE-HCM data to the Myqorzo label: aficamten alone improved peak VO2 by 2.3 mL/kg/min more than metoprolol in obstructive HCM. Results, safety and India access.
